IMPACT OF ANDROGEN DEPRIVATION THERAPY AND OPEN RADICAL RETROPUBIC PROSTATECTOMY ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH PROSTATE CANCER
Abstract
The aim of this study was to show the impact of open radical prostatectomy (ORP) and primary hormone therapy on lower urinary tract symptoms (LUTS) and quality of life (QoL) related to these symptoms based on the International Prostate Symptom Score (IPSS).
A total of 128 patients with localized prostate cancer were analyzed and divided into two groups. The first group consisted of subjects who underwent ORP, and the second group consisted of subjects who were primarily treated with hormone therapy for 12 months. To assess the impact of ORP and hormone therapy on LUTS and QoL, the IPSS and IPSS QoL questionnaires were used before the start of treatment and after 3, 6 and 12 months from the start of treatment.
In both groups of subjects, the IPSSt score consistently significantly decreased during the follow-up period compared to the baseline (p < 0.001 for all). After 12 months IPSSt and IPSSv were significantly higher in group with hormonal therapy compared to ORP group (p < 0.001) and IPSSs was significantly higher ORP group compared to hormonal therapy group. In both groups of subjects, IPSS QoL consistently decreased significantly during the follow-up period (p < 0.001). IPSS Qol was significantly higher in ORP group compared to hormonal therapy group at baseline (p < 0.001), after 3 months (p=0.003), after 6 months (p = 0.002).
ORP and hormone therapy as the primary treatment methods for patients with localized PC led to a statistically significant decrease in IPSS scores and a clinically significant improvement in LUTS. Also, QoL related to LUTS significantly improved in both groups of subjects after 12 months.
References
Bahk JY, Kim MO, Park MS, Lee HY, Lee JH, Chung BC, et al. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int 2008; 80(4):431-8. [CrossRef] [PubMed]
Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J Urol 1992; 148(5):1549-57. [CrossRef] [PubMed]
Bayoud Y, de la Taille A, Ouzzane A, Ploussard G, Allory Y, Yiou R, et al. International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol 2015; 22(3): 283-7. [CrossRef] [PubMed]
Choi H, Chung H, Park JY, Lee JG, Bae JH. The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea. Int Neurourol J 2016; 20(4):342-8. [CrossRef] [PubMed]
Dinić Lj, Bašić D, Ignjatović I, Dinić V, Vuković N, Golubović M et al. The first 10 years’ experience in radical retropubic prostatectomy: complications, lower urinary tract symptoms, and quality of life – a single-center experience. Srp Arh Celok Lek 2021;149(9-10):566-72. [CrossRef]
Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen supression therapy: results from the prostate cancer outcomes study. J Urol 2007; 177:1307-12. [CrossRef] [PubMed]
Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004; 54:617– 21. [CrossRef] [PubMed]
Inoue S, Hayashi T, Teishima J, Matsubara A. Comparative analysis of robot-assisted, laparoscopic, and open radical prostatectomy regarding lower urinary tract symptoms: a longitudinal study. Urol Sci 2020; 31:21-7. [CrossRef]
Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010; 105(8): 1074-81. [CrossRef] [PubMed]
Labrie F, Bélanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005;26(3):361-79. [CrossRef] [PubMed]
Masters JG, Rice ML. Improvement in urinary symptoms after radical prostatectomy: A prospective evaluation of flow rates and symptom scores. BJU Int 2003; 91(9):795-7. [CrossRef] [PubMed]
Matsubara A, Yasumoto H, Teishima J, Seki M, Mita K, Hasegawa Y, et al. Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int J Urol 2006;13(8):1098-102. [CrossRef] [PubMed]
Namiki S, Ishidoya S, Saito S, Satoh M, Tochigi T, Ioritani N, et al. Natural history of voiding function after radical retropubic prostatectomy. Urology 2006; 68(1):142-7. [CrossRef] [PubMed]
Papadopoulos G, Fragkoulis C, Stasinopoulos K, Stathouros G, Glykas I, Theocharis G, et al. Does radical prostatectomy result in lower urinary tract symptom improvement in high-risk and locally advanced prostate cancer? A Single-center experience. Urologia 2021; 88(2):110-14. [CrossRef] [PubMed]
Peyronnet B, Brucker BM. Management of Overactive Bladder Symptoms After Radical Prostatectomy. Curr Urol Rep 2018;19(12):95. [CrossRef] [PubMed]
Porena M, Mearini E, Mearini L, Vianello A, Giannantoni A. Voiding dysfunction after radical retropubic prostatectomy: more than external urethral sphincter deficiency. Eur Urol 2007;52(1):38-45. [CrossRef] [PubMed]
Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71(7):736-47. [CrossRef] [PubMed]
Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, et al. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol 2011; 59(5):868-74. [CrossRef] [PubMed]
Schwartz EJ, Lepor H. Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms. J Urol 1999; 161(4):1185-8. [CrossRef] [PubMed]
Slova D, Lepor H. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms. J Urol 2007; 178(6):2397-400. [CrossRef] [PubMed]
Sun S, Bai Y, Yang H, Yang HW. Investigation on lower urinary tract symptoms (LUTS) in elderly patients with prostate cancer (PC) received endocrine therapy. Arch Gerontol Geriatr 2015;60(3):535-7. [CrossRef] [PubMed]
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49. [CrossRef] [PubMed]
Washino S, Hirai M, Saito K, Kobayashi Y, Arai Y, Miyagawa T. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer. Low Urin Tract Symptoms 2018; 10(1):57-63. [CrossRef] [PubMed]
